A phase 1 open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-001, an anti-CD74 antibody drug conjugate, in patients with advanced B-cell malignancies.

被引：2
|
作者：
Krishnan, Amrita Y.
Shah, Nina
Spira, Alexander I.
Kaufman, Jonathan L.
Niesvizky, Ruben
Shah, Nirav Niranjan
Burke, John M.
Popplewell, Leslie
Martin, Thomas G.
Cheung, Julee
Matheny, Shannon L.
Leonard, John Paul
Molina, Arturo
机构：
[1] City Hope Natl Med Ctr, Duarte, CA USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Virginia Canc Specialists, Fairfax, VA USA
[4] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[5] New York Presbyterian Hosp, Cornell Campus, New York, NY USA
[6] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[7] Rocky Mt Canc Ctr, Aurora, CO USA
[8] Sutro Biopharma, San Francisco, CA USA
[9] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.TPS7586
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7586
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A Phase I open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-001, an anti-CD74 antibody drug conjugate, in patients with advanced B-cell malignancies
    Shah, Nirav N.
    Krishnan, Amrita Y.
    Shah, Nina D.
    Burke, John M.
    Melear, Jason M.
    Spira, Alexander I.
    Kaufman, Jonathan L.
    Cohen, Jonathon B.
    Niesvizky, Ruben
    Popplewell, Leslie L.
    Chhabra, Saurabh
    Sharman, Jeff P.
    Martin, Thomas G.
    Matheny, Shannon L.
    Leonard, John P.
    Molina, Arturo
    CANCER RESEARCH, 2019, 79 (13)
  • [2] Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies
    Shah, Nirav N.
    Krishnan, Amrita Y.
    Shah, Nina D.
    Burke, John M.
    Melear, Jason M.
    Spira, Alexander I.
    Popplewell, Leslie L.
    Andreadis, Charalambos B.
    Chhabra, Saurabh
    Sharman, Jeff P.
    Kaufman, Jonathan L.
    Cohen, Jonathon B.
    Niesvizky, Ruben
    Martin, Thomas G., III
    Dilea, Clifford
    Kuriakose, Jason
    Matheny, Shannon L.
    Leonard, John P.
    Molina, Arturo
    BLOOD, 2019, 134
  • [3] Nonclinical safety evaluation of STRO-001, a site-specific anti-CD74 antibody-drug conjugate for the potential treatment of B-cell malignancies
    Solis, Willy
    De Almeida, Venita
    Yu, Abigail
    Bruhns, Maureen
    Zawada, James
    Galan, Adam
    Matheny, Shannon
    Molina, Arturo
    Hallam, Trevor
    Lupher, Mark
    CANCER RESEARCH, 2018, 78 (13)
  • [4] Preliminary Results of an Ongoing Phase 1 Dose Escalation Study of the Novel Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with B-Cell Non-Hodgkin Lymphoma
    Shah, Nirav N.
    Mattour, Ahmad H.
    Popplewell, Leslie L.
    Andreadis, Charalambos
    Melear, Jason M.
    Spira, Alexander I.
    Shulman, Jonah
    Manda, Sudhir
    Burke, John M.
    Chhabra, Saurabh
    Sharman, Jeff P.
    Krishnan, Amrita
    Shah, Nina
    Dilea, Clifford
    Kuriakose, Jason
    Berman, Craig Jerome
    Matheny, Shannon L.
    Leonard, John P.
    Molina, Arturo
    BLOOD, 2020, 136
  • [5] STRO-001, A NOVEL ANTI-CD74 ANTIBODY DRUG CONJUGATE (ADC) FOR TREATMENT OF B-CELL NON-HODGKIN'S LYMPHOMA (NHL)
    Yu, A.
    Abrahams, C.
    Embry, M.
    Li, X.
    DeAlmeida, V.
    Lee, J.
    Matheny, S.
    Kline, T.
    Yam, A.
    Stafford, R.
    Hallam, T.
    Lupher, M.
    Molina, A.
    HAEMATOLOGICA, 2017, 102 : 564 - 564
  • [6] CD74 Is Expressed in Relapsed and Refractory Multiple Myeloma and Can be Targeted with a Novel Anti-CD74 Antibody Drug Conjugate, STRO-001
    Embry, Millicent
    Li, Xiaofan
    Yu, Abigail
    Abrahams, Cristina
    Greenland, Nancy Y.
    Wen, Kwun Wah
    Jones, Chris
    DeAlmeida, Venita
    Krimm, Stellanie
    Krueger, Sarah
    Matheny, Shannon
    Kline, Toni
    Yam, Alice
    Stafford, Ryan
    Wiita, Arun P.
    Hallam, Trevor
    Lupher, Mark
    Molina, Arturo
    BLOOD, 2017, 130
  • [7] Characterization and preclinical development of STRO-001, a novel CD74-targeting antibody-drug conjugate (ADC) for the treatment of B-cell malignancies
    Abrahams, Cristina
    Li, Xiaofan
    DeAlmeida, Venita
    Embry, Millicent
    Yu, Abigail
    Krim, Stellanie
    Hoffmann, Heidi
    Zawada, James
    Bruhns, Maureen
    Matheny, Shannon
    Bussell, Stuart
    Kline, Toni
    Yam, Alice
    Stafford, Ryan
    Hallam, Trevor
    Lupher, Mark
    Molina, Arturo
    CANCER RESEARCH, 2017, 77
  • [8] Preclinical evaluation of a humanized anti-CD74 monoclonal antibody hLL1, for treatment of B-cell malignancies.
    Stein, R
    Burton, JD
    Cardillo, TM
    Qu, ZX
    Ely, SA
    Reddy, P
    Chen, S
    Rosario, A
    Horak, ID
    Hansen, HJ
    Goldenberg, DM
    BLOOD, 2003, 102 (11) : 181A - 181A
  • [9] Anti-CD74 antibody therapy with hLL1 (milatuzumab) for treatment of B-cell malignancies
    Martin, P.
    Furman, R.
    Elstrom, R.
    Ruan, J.
    Shore, T.
    Ely, S.
    Glynn, P.
    Niesvizky, R.
    Coleman, M.
    Sharkey, R.
    Vallabhajosula, S.
    Goldsmith, S.
    Goldenberg, D. M.
    Leonard, J. P.
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2008, 23 (04) : 525 - 525
  • [10] High Frequency of CD74 Expression in B-Cell Non-Hodgkin's Lymphoma (NHL) and Targeting with STRO-001, a Novel Anti-CD74 Antibody Drug Conjugate (ADC) with Potent I n Vitro Cytotoxicty and In Vivo Anti-Tumor Activity
    Yu, Abigail
    Abrahams, Cristina
    Embry, Millicent
    Li, Xiaofan
    Zhao, Shuchun
    Henningsen, Robert
    DeAlmeida, Venita
    Matheny, Shannon
    Kline, Toni
    Yam, Alice
    Stafford, Ryan
    Natkunam, Yasodha
    Hallam, Trevor
    Lupher, Mark
    Molina, Arturo
    BLOOD, 2017, 130
12345